By Including a TGFβ siRNA and a Cox 2 siRNA in a single nanoparticle for systemic delivery and monitoring its effect on HCC in a mouse model, we benefit from silencing each target gene which enables greater penetration and intra-tumoral trafficking of CD4+ and CD8+ T cells. The gene discussed is CD8A; the disease is hepatocellular carcinoma.